July 2015 Fact Sheet

Head Office

Pieris Pharmaceuticals, Inc.
Lise-Meitner-Strasse 30
85354 Freising
Germany

+49 (0) 8161 1411 400

For more information:
info@pieris.com

www.pieris.com

For business development / partnering enquiries, please contact Eckhard Niemeier, VP BD:
niemeier@pieris.com

For investor relations enquiries, please contact Darlene Deptula-Hicks, CFO:
deptula@pieris.com

Company Overview

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that may help patients suffering from cancer, asthma, anemia and other medical conditions with a high unmet medical need. Pieris has a diverse pipeline of Anticalin® therapeutics and has R&D collaborations with several partners.

Pieris has been funded by premier venture capital firms, with OrbiMed as its lead investor. In December 2014, Pieris became a publicly traded company.

Pieris Strategy

- Advance its lead drug candidates, PRS-080 (hepcidin) and PRS-060 (IL4Ra), into and through clinical trials
- Develop its immuno-oncology franchise
- Continue to exploit its platform through new and existing partnerships

Anticalin® Proteins

Anticalins are based on human lipocalins, proteins that naturally bind and transport different molecules throughout the body. Our diverse libraries of more than 100 billion different Anticalins ensure a high probability of obtaining a drug candidate against virtually any target of interest. Anticalins can be genetically linked to each other or to monoclonal antibodies, creating multispecific molecules with a broad range of therapeutic applications.



Differentiation from Antibodies

- Formatting flexibility for multispecific drugs
- Alternative delivery routes (e.g. inhaled)
- Cheaper bacterial expression
- Tunable kinetics to match biological need
- Dominant patent position and full FTO

Figures

Key Numbers

Ticker: (NASDAQ: PIRS)
Share price: $2.85 (as of 7/23/15)
Market Cap: $109.8M
Revenue (3 months): $0.2M (as of 03/31/15)
Net Loss (3 months): $3.7M (as of 03/31/15)
Cash: $13.2M (as of 03/31/2015)
Total revenues: $58M
Total capital raised: $108.4M

Partners

Stelis Biopharma — **December 2013:** Co-development of first-in-class Anticalin® therapeutics in ophthalmology.

Zydus dedicated to life — **October 2013:** Co- development of novel Anticalin® therapeutics, including cMet.

Daiichi-Sankyo — **April 2011:** Discovery and development partnership on novel Anticalin® therapeutics against two targets.

SANOFI — **September 2010:** Multi-year, multi-target collaboration with both Sanofi and Sanofi Pasteur across a broad spectrum of indications.

ALLERGAN — **September 2009:** Discovery of novel treatments for serious ocular disorders.

Product Pipeline



Catalysts:

Q2/Q3 2015: Milestone achievements for partnered programs

Q3 2015: *PRS-080 Anemia* – Phase I data; anti-hepcidin Anticalin® therapeutic protein

H2 2015: *PRS-300 Immuno-Oncology* – In vivo Proof-of-Concept and Drug Candidate Nomination for multispecific program

Q4 2015: *PRS-080 Anemia* – Initiation of Phase Ib/IIa

Proprietary Programs Highlights

PRS-080 - Anemia



- Lead program against hepcidin
- Targets the large markets of anemia in CKD and cancer
- Tuned kinetics to address target biology
- Phase I in healthy volunteers started in November 2014
- Biomarker-driven Phase II efficacy trial planned thereafter

PRS-060 – Respiratory Diseases

- Preclinical program against IL4Ra
- Targets asthma and other respiratory diseases
- Differentiates from antibodies against IL-4 and IL-13 through inhaled delivery directly into the lungs, potentially resulting in improved efficacy and safety
- Local delivery is more convenient for patients and allows for very low doses, potentially resulting in a significant cost of goods advantage over systemic mAbs

PRS-300s – Immuno-Oncology



- Tumor localized immune activation with multi-specifics may lead to improved efficacy over current tumor-targeted therapies and may avoid systemic side effects of mono-specific immunomodulatory mAbs

PRS-343 – CD137-HER2 Bispecific

- **CD137**: Costimulatory target on tumor-reactive T cells; mAbs struggle to find therapeutic window
- **HER2**: validated target across broad spectrum of solid tumors; not adequately addressed in all patients with current therapy
- **Bispecific immunotherapy** may offer broader therapeutic window and expand responding patient population